December 27, 2016: Alliqua BioMedical has exploded higher on FDA marketing approval for an ultrasound wound care system. The FDA 510K clearance decision date is noted as 12/22. Source: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K162721
November 8, 2016: Rodman & Renshaw/ H.C. Wainwright reiterates a Buy rating on Alliqua BioMedical and sets a price target of $2.50.
Alliqua BioMedical Stock Chart
Alliqua is a provider of advanced wound care solutions.